The financials
Caris Life Sciences, Inc. by the numbers
Caris Life Sciences, Inc. (CAI) reported revenue of $264M in Q2 2026 (quarter ended June 30, 2026), up 45% from the same quarter a year earlier. That came with net loss of $637K. For the full year FY2025, revenue was $812M (+97% year on year) and net income −$68M. Its largest product in 2026-Q1 was Molecular Profiling Services at $211M, 98% of the disclosed total, just ahead of Pharma Research And Development Services at 2.5%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $264M | $181M | +45% |
| Operating income | $27M | −$18M | to a profit |
| Net income | −$637K | −$72M | n/a |
| Diluted EPS | $0.00 | −$7.97 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Molecular Profiling Services | $211M | 98% |
| Pharma Research And Development Services | $5.4M | 2.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $216.2M (-0.30%)
Molecular Profiling Services grew +85% year on yearPharma Research And Development Services -21% year on year
Segment Latestquarter on quarteryear on year
- Molecular Profiling Services$210.8M$210.8MQoQ +1.5%year on year +85%+1.5%+85%
- Pharma Research And Development Services$5.4M$5.4MQoQ -42%year on year -21%-42%-21%